S E Singletary

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Minimally invasive operation for breast cancer
    S Eva Singletary
    University of Texas M.D. Anderson Cancer Center, Houston, USA
    Curr Probl Surg 41:394-447. 2004
  2. ncbi Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer
    S E Singletary
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, TX 77030, USA
    Am J Surg 182:341-6. 2001
  3. ncbi Breast cancer management: the road to today
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:1844-9. 2008
  4. ncbi Introduction of Dr. Alfred M. Cohen
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, TX 77030-4095, USA
    Ann Surg Oncol 11:795-7. 2004
  5. ncbi Minimally invasive techniques in breast cancer treatment
    S E Singletary
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Semin Surg Oncol 20:246-50. 2001
  6. ncbi Revision of breast cancer staging: the 6th edition of the TNM Classification
    S Eva Singletary
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Semin Surg Oncol 21:53-9. 2003
  7. ncbi Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual
    S Eva Singletary
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 106, Houston, TX 77030 4009, USA
    Surg Clin North Am 83:803-19. 2003
  8. ncbi A role for curative surgery in the treatment of selected patients with metastatic breast cancer
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, Texas 77030 4095, USA
    Oncologist 8:241-51. 2003
  9. ncbi Feasibility of radiofrequency ablation for primary breast cancer
    Eva S Singletary
    Department of Surgical Oncology, Box 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer 10:4-9. 2003
  10. ncbi Minimally invasive surgery in breast cancer treatment
    S E Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Biomed Pharmacother 55:510-4. 2001

Detail Information

Publications102 found, 100 shown here

  1. ncbi Minimally invasive operation for breast cancer
    S Eva Singletary
    University of Texas M.D. Anderson Cancer Center, Houston, USA
    Curr Probl Surg 41:394-447. 2004
  2. ncbi Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer
    S E Singletary
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, TX 77030, USA
    Am J Surg 182:341-6. 2001
    ....
  3. ncbi Breast cancer management: the road to today
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:1844-9. 2008
    ..These articles are extraordinary not only for breaking new ground in their respective technical areas, but also for the keen insights shown by the authors into what would become important in the future...
  4. ncbi Introduction of Dr. Alfred M. Cohen
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, TX 77030-4095, USA
    Ann Surg Oncol 11:795-7. 2004
  5. ncbi Minimally invasive techniques in breast cancer treatment
    S E Singletary
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Semin Surg Oncol 20:246-50. 2001
    ..This new frontier of surgery without scalpels will require surgeons to develop radiologic expertise and to acquire a basic understanding of molecular biology...
  6. ncbi Revision of breast cancer staging: the 6th edition of the TNM Classification
    S Eva Singletary
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Semin Surg Oncol 21:53-9. 2003
    ..Revisions of the previous staging system are related to the number of affected axillary lymph nodes and to the classification of level III axillary lymph nodes and lymph nodes outside of the axilla...
  7. ncbi Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual
    S Eva Singletary
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 106, Houston, TX 77030 4009, USA
    Surg Clin North Am 83:803-19. 2003
    ..By increasing the number of prognostic markers that can give independent information about patient outcome, physicians will be better able to determine optimal treatment approaches for individual patients...
  8. ncbi A role for curative surgery in the treatment of selected patients with metastatic breast cancer
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, Texas 77030 4095, USA
    Oncologist 8:241-51. 2003
    ..The addition of chest x-rays as part of routine follow-up should be considered as a cost-effective approach for early assessment of metastases to the lung or sternum that may be appropriate for surgical excision...
  9. ncbi Feasibility of radiofrequency ablation for primary breast cancer
    Eva S Singletary
    Department of Surgical Oncology, Box 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer 10:4-9. 2003
    ..Successful ablation will be determined by core and fine needle biopsies, and long-term outcomes will be assessed using imaging studies and quality of life measurement scales for 5 years following treatment...
  10. ncbi Minimally invasive surgery in breast cancer treatment
    S E Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Biomed Pharmacother 55:510-4. 2001
    ..This article will discuss such techniques in three evolving areas: 1) management of the axilla after neoadjuvant chemotherapy; 2) sentinel node dissection; and 3) radiofrequency ablation of primary tumors of the breast...
  11. ncbi Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy
    S Eva Singletary
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston TX 77030 4095, USA
    Am J Surg 184:383-93. 2002
    ..This review examines published reports about standard and innovative approaches to assessing surgical margins, the clinical significance of margin size, and risk factors for positive margins...
  12. ncbi Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2835-42. 2002
    ..Surrogate end point biomarkers (SEBs) that can be measured in ductal carcinoma in situ or early-stage invasive cancer are needed to improve the efficiency and reduce the cost of chemoprevention trials...
  13. ncbi Revision of the American Joint Committee on Cancer staging system for breast cancer
    S Eva Singletary
    University of Texas M D Anderson Cancer Center and Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 20:3628-36. 2002
    ..To revise the American Joint Committee on Cancer staging system for breast carcinoma...
  14. ncbi Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base
    S Eva Singletary
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    Ann Surg 242:281-9. 2005
    ..To examine treatment trends in invasive lobular carcinoma (ILC) over the last 15 years and, in particular, to compare rates of recurrence and disease-free survival associated with breast conservation therapy compared with mastectomy...
  15. ncbi Rating the risk factors for breast cancer
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, TX 77030 4095, USA
    Ann Surg 237:474-82. 2003
    ..To update and summarize evidence of risk factors for breast cancer...
  16. ncbi Surgical management of inflammatory breast cancer
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Semin Oncol 35:72-7. 2008
    ..However, there are no medical contraindications to breast reconstruction after mastectomy, although most clinicians prefer to wait until after the completion of radiotherapy before attempting this additional surgery...
  17. ncbi Mentoring surgeons for the 21st century
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, Texas 77030, USA
    Ann Surg Oncol 12:848-60. 2005
    ..Effective mentoring is especially critical in the training of surgeons. The practice of surgery in the 21st century is changing rapidly at every level, requiring a more complex approach to mentoring young surgeons...
  18. ncbi Defining the clinical diagnosis of inflammatory breast cancer
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Semin Oncol 35:7-10. 2008
    ..Accurate diagnosis is critically important, as multimodal therapy can significantly improve outcomes if instituted early enough...
  19. ncbi Breast cancer surgery for the 21st century: the continuing evolution of minimally invasive treatments
    S E Singletary
    Department of Surgical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    Minerva Chir 61:333-52. 2006
    ..These deficits may be filled by future developments in functional imaging (e.g., positron emission tomography) and nanobiotechnology...
  20. ncbi Multidisciplinary frontiers in breast cancer management: a surgeon's perspective
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 109:1019-29. 2007
    ..It will be important for surgeons to stay aware of all developments that may improve the care of their patients and to be true surgical oncologists rather than merely surgical technicians...
  21. ncbi Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
    G N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Natl Cancer Inst 92:225-33. 2000
    ..We conducted a prospective randomized trial to compare standard-dose chemotherapy with the same therapy followed by high-dose chemotherapy. PATIENTS and..
  22. ncbi Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases
    G Vlastos
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
    Ann Surg Oncol 8:425-31. 2001
    ..0001). CONCLUSIONS: Occult primary carcinoma with axillary metastases can be treated with preservation of the breast without a negative impact on local control or survival...
  23. ncbi Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy
    T A Buchholz
    Departments of Radiation Oncology, Biomathematics, Breast Medical Oncology, and Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:2240-6. 2001
    ..To determine the impact of tamoxifen and chemotherapy on local control for breast cancer patients treated with breast-conservation therapy...
  24. ncbi Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant
    T A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 46:337-43. 2000
    ..To determine local-regional failure rates in breast cancer patients treated with surgery and high-dose chemotherapy with stem cell transplant and to relate local-regional failure to the use and timing of radiation treatment...
  25. ncbi New approaches to surgery for breast cancer
    S E Singletary
    The University of Texas M D Anderson Cancer Center, Department of Surgical Oncology, Houston, Texas 77030, USA
    Endocr Relat Cancer 8:265-86. 2001
    ..These new, less invasive approaches require the close cooperation of a team of physicians,including surgeons, pathologists, radiologists, and medical and radiation oncologists...
  26. ncbi Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
    A U Buzdar
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:3412-7. 1999
    ..To compare prospectively the antitumor activity of single-agent paclitaxel to the three-drug combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC) as neoadjuvant therapy in patients with operable breast cancer...
  27. ncbi Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience
    R A Brito
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:628-33. 2001
    ....
  28. ncbi Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience
    G Vlastos
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 92:1092-100. 2001
    ..This treatment should be considered as the standard of care for elderly patients without severe comorbid disease...
  29. ncbi Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer
    L A Newman
    Department of Surgical Oncology, Box 444, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Surg 181:313-8. 2001
    ....
  30. ncbi Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy
    Anees B Chagpar
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
    Ann Surg 243:257-64. 2006
    ..CONCLUSION: Physical examination, ultrasonography, and mammography were only moderately useful for predicting residual pathologic tumor size after neoadjuvant chemotherapy...
  31. ncbi The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy
    A Katz
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 50:735-42. 2001
    ..These factors predict for high LRR rates regardless of the number of involved axillary nodes...
  32. ncbi Educational review: role of the surgeon in hereditary breast cancer
    L A Newman
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Ann Surg Oncol 8:368-78. 2001
    ..The reported literature in this area, including a discussion of the value of genetic counseling and genetic testing, is reviewed...
  33. ncbi A case-control study of unilateral and bilateral breast carcinoma patients
    L A Newman
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Cancer 91:1845-53. 2001
    ....
  34. ncbi T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy
    Amit K Garg
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:138-45. 2004
    ..For most patients with clinical T1 or T2 disease and one to three positive lymph nodes, the 5-year risk for LRR was low, and the routine inclusion of postmastectomy radiotherapy does not appear to be justified...
  35. ncbi Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation
    A Katz
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 50:397-403. 2001
    ..Patients with 20% or greater involved nodes and those with less than 20% nodes and tumors of 5.0 cm or greater are at significant risk of LRR and should be considered for postoperative irradiation...
  36. ncbi Locoregional treatment outcomes after multimodality management of inflammatory breast cancer
    Ian J Bristol
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:474-84. 2008
    ....
  37. ncbi Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge
    Neslihan Cabioglu
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:508-17. 2004
    ..Nonetheless, BCS can be performed safely if negative margins are achieved and if appropriate adjuvant radiotherapy or systemic therapy is administered...
  38. ncbi Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry
    Anees Chagpar
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:1581-6. 2005
    ..543 and P = 0.540, respectively). CONCLUSIONS: Although the finding of SLN micrometastases by IHC may change management in > 12% of patients, preliminary results suggested that such micrometastases do not affect outcomes significantly...
  39. ncbi Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer
    Rosa F Hwang
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 10:248-54. 2003
    ..A scoring system incorporating these factors may help determine which patients would benefit from additional axillary surgery...
  40. ncbi High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer
    Henry M Kuerer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:601-5. 2003
    ..Breast ductal fluid can be obtained from women by simple nipple aspiration and may be useful for analyzing the microenvironment of the breast...
  41. ncbi Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ
    Tina W F Yen
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:942-9. 2004
    ..The current findings have implications for current trials evaluating aromatase inhibitors and other chemopreventive agents for this disease...
  42. ncbi Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years
    Attiqa N Mirza
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg 235:10-26. 2002
    ..Because of technical difficulties and variations in the measurement of many of these factors, tumor size and tumor grade remain the only markers that currently have broad clinical usefulness for this patient group...
  43. ncbi Radiofrequency ablation of solid tumors
    A N Mirza
    Department of Surgical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA
    Cancer J 7:95-102. 2001
    ..An ongoing study is investigating the use of radiofrequency ablation for the treatment of breast tumors 2 cm or less in diameter...
  44. ncbi New clinical trends in the adjuvant therapy of early stage breast cancer
    S E Singletary
    Department of Surgical Oncology, M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Acta Oncol 37:411-9. 1998
    ....
  45. ncbi US-guided implantation of metallic markers for permanent localization of the tumor bed in patients with breast cancer who undergo preoperative chemotherapy
    B S Edeiken
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Radiology 213:895-900. 1999
    ..This technique effectively addresses the problem of preoperative localization of the tumor bed in complete or nearly complete response of breast cancer to neoadjuvant chemotherapy...
  46. ncbi Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer
    D Albo
    Department of Surgical Oncology, Box 444, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Surg 182:393-8. 2001
    ..Lymphatic mapping with blue dye should be performed in a setting where personnel are trained to recognize and treat anaphylaxis...
  47. ncbi The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy
    Florentia Peintinger
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:1248-54. 2006
    ..Prospective studies are needed to examine whether decreasing the RVs in this patient population leads to an increased LRR rate...
  48. ncbi A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility
    Lisa A Newman
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Ann Surg Oncol 9:228-34. 2002
    ..Improved breast imaging methods after chemotherapy are necessary to improve accuracy in predicting the feasibility of BCT, especially in patients presenting with diffuse calcifications or multicentricity...
  49. ncbi Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy
    Nadeem Q Mirza
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 9:256-65. 2002
    ..Disease-specific survival among patients with LRR was similar to that among patients with no recurrence. CONCLUSIONS: Multidisciplinary treatment strategies should be used to accomplish durable locoregional control after BCT...
  50. ncbi Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience
    Allen M Chen
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:2303-12. 2004
    ..Advanced nodal involvement at diagnosis, residual tumor larger than 2 cm, multifocal residual disease, and lymphovascular space invasion predict higher rates of LRR and IBTR...
  51. ncbi Improving local control with breast-conserving therapy: a 27-year single-institution experience
    Neslihan Cabioglu
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:20-9. 2005
    ..The current low incidence of IBTR with multidisciplinary management of breast carcinoma may result in more patients choosing BCT over mastectomy...
  52. ncbi Local recurrence risk after skin-sparing and conventional mastectomy: a 6-year follow-up
    S S Kroll
    Department of Plastic Surgery, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Plast Reconstr Surg 104:421-5. 1999
    ..We conclude that the use of skin-sparing technique for early breast cancer patients does not significantly increase the risk of tumor recurrence after mastectomy...
  53. ncbi Systemic treatment after sentinel lymph node biopsy in breast cancer: who, what, and why?
    S E Singletary
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    J Am Coll Surg 192:220-30. 2001
    ..Because of the significant frequency of false-negative results in SLNB, which will depend upon the surgeon's experience, caution is urged in determining when ALND can be safely eliminated in patients with a negative SLNB...
  54. ncbi Reduction mammoplasty improves breast conservation therapy in patients with macromastia
    L A Newman
    Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Surg 181:215-20. 2001
    ..Patient survey revealed a satisfaction rate of 86%. CONCLUSION: Bilateral reduction mammoplasty is a reasonable and safe option for breast cancer patients with macromastia who desire breast conservation therapy...
  55. ncbi Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma
    Jeannie Shen
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Cancer 101:1330-7. 2004
    ..Identification of malignant intraMLNs by lymphatic mapping may help to identify high-risk patients for whom further evaluation of the axillary lymph nodes is warranted despite otherwise clinically negative findings in the axilla...
  56. ncbi Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence
    Jeannie Shen
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 104:479-90. 2005
    ..Determinants of prognosis after IBTR should be taken into account when evaluating the need for further systemic therapy and designing risk-stratified clinical trials...
  57. ncbi Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy
    Florentia Peintinger
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 13:1443-9. 2006
    ..Agreement of residual tumor size in mammography and sonography with pathologic residual tumor size was moderate...
  58. ncbi Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy
    Linda J Adepoju
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:42-50. 2006
    ..Concurrent ADH, ALH, or LCIS with DCIS is not a contraindication to BCT...
  59. ncbi Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy
    Laura A Lambert
    Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Ann Surg Oncol 13:310-20. 2006
    ..TIC seems to be an acceptable substitute for frozen section as a nomogram variable. The nomogram may help predict an individual's risk of non-SLN metastases and assist in patient decision making regarding the benefit of CLND...
  60. ncbi Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer
    Kazumi Kawase
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 203:64-72. 2006
    ..Longterm followup of patients with lymphoscintigraphic evidence of extraaxillary drainage is needed to determine whether regional and systemic recurrence patterns differ in these patients...
  61. ncbi Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction
    Anees Chagpar
    Department of Surgical Oncology, Box 444, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Surg 187:164-9. 2004
    ..Collaboration with a plastic surgery team may be beneficial in the surgical management of these patients...
  62. ncbi Treatment and outcome of patients with intracystic papillary carcinoma of the breast
    Carmen C Solorzano
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg 184:364-8. 2002
    ..Intracystic papillary carcinoma (IPC) of the breast is a rare form of noninvasive breast cancer. An appreciation of associated pathology with IPC may be critical in surgical decision-making...
  63. ncbi Role for intraoperative margin assessment in patients undergoing breast-conserving surgery
    Neslihan Cabioglu
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, 77030, USA
    Ann Surg Oncol 14:1458-71. 2007
    ..We investigated whether intraoperative margin assessment aids in obtaining negative margins, and to evaluate the local control thus achieved...
  64. ncbi Expression of ERalpha and ERbeta in lobular carcinoma in situ
    L P Middleton
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Histopathology 50:875-80. 2007
    ..The aim of this study was to examine ER expression in LCIS to determine the relationship of ERalpha to ERbeta and, thereby, to determine whether it is of clinical value to measure ERbeta along with ERalpha...
  65. ncbi Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma
    H M Kuerer
    Department of Surgical Oncology, Box 444, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Surg 182:601-8. 2001
    ..Resection of the tumor bed remains necessary in women deemed to have a complete clinical response to ensure low rates of recurrence...
  66. ncbi Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively
    R Vassilopoulou-Sellin
    Department of Breast and Gynecologic Medical Oncology, M D Anderson Cancer Center, University of Texas, Houston 77030, USA
    J Clin Oncol 17:1482-7. 1999
    ..To determine whether estrogen replacement therapy (ERT) alters the development of new or recurrent breast cancer in women previously treated for localized breast cancer...
  67. ncbi Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast
    H M Kuerer
    Department of Surgical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Surg Oncol 77:139-47. 2001
    ..These trials will answer some of the many questions that remain regarding optimal hormonal therapy for hormone-dependent breast cancer...
  68. ncbi Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer
    Isabelle Bedrosian
    Departments of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 10:1025-30. 2003
    ..No significant clinicopathologic criteria were found to impact sensitivity of ultrasonography; however, excisional biopsy for diagnosis may be a confounding variable in subsequent axillary ultrasonography...
  69. ncbi Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ
    Tina W F Yen
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 200:516-26. 2005
    ..Risks and benefits of SLNB should be discussed with patients who are younger, are diagnosed by core-needle biopsy, or have large or high-grade DCIS...
  70. ncbi Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences
    Eugene Huang
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 95:2059-67. 2002
    ..This is because patients with new carcinomas had significantly lower rates of metastasis than those with local disease recurrence, but were more likely to develop contralateral breast carcinomas...
  71. ncbi Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy
    Jeannie Shen
    Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Ann Surg Oncol 11:854-60. 2004
    ..These patients have favorable rates of long-term local control and survival. Mastectomy is not mandatory for all patients with breast cancer who present with skin involvement...
  72. ncbi Long-term complications associated with breast-conservation surgery and radiotherapy
    Funda Meric
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Ann Surg Oncol 9:543-9. 2002
    ..Breast-conservation surgery and radiotherapy is associated with grade 2 or greater complications in only 9.9% of patients. Nearly half of these complications are attributable to axillary dissection...
  73. ncbi Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge
    Neslihan Cabioglu
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 196:354-64. 2003
    ..In patients with pathologic discharge with normal findings on physical examination and other imaging studies, ductography might be the only means of localizing and resecting breast lesions associated with nipple discharge...
  74. ncbi Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloid
    C C Solorzano
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Ann Surg Oncol 8:821-7. 2001
    ..The delay between injection and surgery did not appear to promote significant passage of sulfur colloid to second-echelon nodes...
  75. ncbi Prospective, randomized, double-blind study of prophylactic antibiotics in axillary lymph node dissection
    R J Bold
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Surg 176:239-43. 1998
    ..Antibiotic prophylaxis is controversial in patients undergoing axillary lymph node dissection (ALND). We determined whether preoperative antibiotics decreased incidence or treatment cost of infectious complications following ALND...
  76. ncbi Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy
    Bryan T Hennessy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:9304-11. 2005
    ..The purpose of this study was to determine long-term outcome in patients achieving pCR of cytologically proven axillary lymph node (ALN) metastases...
  77. ncbi The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, Breast Medical Oncology, Surgical Oncology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:8398-402. 2005
    ....
  78. ncbi Chest wall recurrence after mastectomy does not always portend a dismal outcome
    Anees Chagpar
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 10:628-34. 2003
    ..0001). CONCLUSIONS: Patients with CWR are a heterogeneous population. Patients with initial node-negative disease who develop CWR after 24 months have an optimistic prognosis, especially if they are treated with radiation...
  79. ncbi Paget's disease of the breast: there is a role for breast-conserving therapy
    Kazumi Kawase
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, Texas 77030, USA
    Ann Surg Oncol 12:391-7. 2005
    ..CONCLUSIONS: Paget's disease of the breast is almost always associated with an underlying breast cancer. Breast-conserving approaches result in local control and survival rates similar to those achieved with mastectomy...
  80. ncbi Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1073-9. 2002
    ..In this prospective randomized trial, the role of paclitaxel was evaluated in an adjuvant setting to determine its impact on reducing the risk of recurrence in patients with operable breast cancer...
  81. ncbi Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:880-8. 2002
    ..To compare the pathologic factors associated with postmastectomy locoregional recurrence (LRR) in breast cancer patients not receiving radiation who were treated with neoadjuvant chemotherapy (NEO) vs. adjuvant chemotherapy (ADJ)...
  82. ncbi Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 65:1155-60. 2006
    ....
  83. ncbi Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:676-81. 2005
    ..To the authors' knowledge there are few data that correlate the expression of the epidermal growth factor receptor (EGFR) with the outcome of patients who have breast carcinoma and are treated with anthracycline chemotherapy...
  84. ncbi Multidisciplinary management of breast cancer concurrent with pregnancy
    Angela J Keleher
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    J Am Coll Surg 194:54-64. 2002
    ..Above all, the patient with breast cancer diagnosed during pregnancy is best served by early and continued involvement of a multidisciplinary cancer treatment team...
  85. ncbi Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy
    Bryan T Hennessy
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1000-6. 2006
    ..The purpose of the current study was to determine long-term outcome in patients achieving a pCR of cytologically proven inflammatory breast carcinoma ALN metastases after primary chemotherapy...
  86. ncbi Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer
    Eugene Huang
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:1225-33. 2002
    ..Alternative therapeutic strategies such as novel systemic agents, use of planned myocutaneous repair for closure, or radiation combined with radiosensitizing agents, should be considered in this class of patients...
  87. ncbi Breast conservation after neoadjuvant chemotherapy
    Allen M Chen
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:689-95. 2005
    ..The MDAPI enabled the identification of a small group (4%) of patients who are at high risk for IBTR and LRR and who may benefit from alternative locoregional treatment strategies...
  88. ncbi Nipple aspirate fluid cytology in breast carcinoma
    Savitri Krishnamurthy
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 99:97-104. 2003
    ..Cytologic-histologic correlations of NAF were performed in only a few studies...
  89. ncbi Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 20:17-23. 2002
    ..To define clinical and pathologic predictors of local-regional recurrence (LRR) for patients treated with neoadjuvant chemotherapy and mastectomy without radiation...
  90. ncbi Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites
    Funda Meric
    Section of Breast Surgery, Department of Surgical Oncology, University of Texas, USA
    BMJ 324:577-81. 2002
    ..To determine the characteristics of popular breast cancer related websites and whether more popular sites are of higher quality...
  91. ncbi Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy
    Funda Meric
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 97:926-33. 2003
    ....
  92. ncbi Breast cancer recurrence after immediate reconstruction: patterns and significance
    Howard N Langstein
    Department of Plastic Surgery, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Plast Reconstr Surg 111:712-20; discussion 721-2. 2003
    ..These data support the continued use of immediate breast reconstruction without fear of concealing a recurrence or influencing the oncologic outcome...
  93. ncbi Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study
    Savitri Krishnamurthy
    Department of Cytopathology, Unit 53, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 102:322-7. 2004
    ....
  94. ncbi Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer
    Judy C Boughey
    Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 244:464-70. 2006
    ..05). CONCLUSIONS: Among patients treated with BCT for larger breast tumors, patients treated with preoperative chemotherapy have less extensive resection, with no change in rates of re-excision...
  95. ncbi Reconstructive management of contralateral breast cancer in patients who previously underwent unilateral breast reconstruction
    D W Chang
    Department of Plastic Surgery and Surgical Oncology, The University of Texas M D Anderson Cancer Center Houston, TX 77030, USA
    Plast Reconstr Surg 108:352-8; discussion 359-60. 2001
    ..The best result is obtained when similar methods and tissues are used on both sides...
  96. ncbi DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway
    S C Wang
    Department of Molecular and Cellular Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Oncogene 20:6960-4. 2001
    ....
  97. ncbi Sensitivity to benzo(a)pyrene diol-epoxide associated with risk of breast cancer in young women and modulation by glutathione S-transferase polymorphisms: a case-control study
    P Xiong
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 61:8465-9. 2001
    ..Larger studies are needed to confirm our findings...
  98. ncbi Timing of surgical intervention for the intact primary in stage IV breast cancer patients
    Roshni Rao
    Division of Surgical Oncology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9155, USA
    Ann Surg Oncol 15:1696-702. 2008
    ..The subset of patients who would most benefit from surgery remains unclear. This study evaluates the pathological attributes and optimum timing for surgery in patients who present with stage IV breast cancer and an intact primary...
  99. ncbi Overview of adjuvant systemic therapy in early stage breast cancer
    Lisa A Newman
    Breast Care Center, 1500 East Medical Center Drive, 3308 CGC, University of Michigan, Ann Arbor, MI 48109, USA
    Surg Clin North Am 87:499-509, xi. 2007
    ..Ongoing clinical and translational research in breast cancer seeks to improve the efficacy of systemic agents for use in the conventional postoperative (adjuvant) setting...
  100. ncbi Candidates for minimally invasive therapy of breast cancer: redefining the standards
    S Eva Singletary
    Ann Surg Oncol 10:591-2. 2003
  101. ncbi Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study
    Jeanne A Petrek
    Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:1045-51. 2006
    ..CONCLUSION: Using daily menstrual bleeding records, it is demonstrated that age, the specific chemotherapy regimen received, and tamoxifen use impact ovarian function...